Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A R Nestel
Comment On: ‘One-Year Real-World Outcomes in Patients Receiving Fixed-Dosing Aflibercept for Neovascular Age-Related Macular Degeneration’
Eye
Medicine
Arts
Sensory Systems
Ophthalmology
Humanities
Related publications
Aflibercept for Neovascular Age-Related Macular Degeneration
Cochrane Database of Systematic Reviews
Clinical Experience With Fixed Bimonthly Aflibercept Dosing in Treatment-Experienced Patients With Neovascular Age-Related Macular Degeneration
Clinical Ophthalmology
Ophthalmology
One Year Effectiveness Study of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: A Meta-Analysis
Acta Ophthalmologica
Medicine
Ophthalmology
Treat-And-Extend Therapy Using Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: 2-Year Real-World Practice Data From Slovenia
BMC Ophthalmology
Medicine
Ophthalmology
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration in Patients Aged 90 Years or Older: 2-Year Visual Acuity Outcomes
Eye
Medicine
Arts
Sensory Systems
Ophthalmology
Humanities
Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration
Acta Ophthalmologica
Medicine
Ophthalmology
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Scientific Reports
Multidisciplinary
Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology
Ophthalmology
Comment on ‘Transitioning to Intravitreal Aflibercept Following a Previous Treat-And-Extend Dosing Regimen in Neovascular Age-Related Macular Degeneration: 24-Month Results’
Eye
Medicine
Arts
Sensory Systems
Ophthalmology
Humanities
